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CONSIDER THESE NUMBERS:
1 OUT OF EVERY 4 WOMEN
225
MILLION

in low- and middle-income countries
want to delay or prevent pregnancy
but are not using a modern
contraceptive method.

EVERY DAY NEARLY

6,300 PEOPLE

become infected with
HIV, disproportionately
affecting young women aged
15-24 in pandemic regions.

New prevention options
aimed at reducing
unintended pregnancy
and the transmission of
HIV and other STIs are
urgently needed.

The Population Council
is meeting this challenge
by developing new
technologies and products
to help people enhance
their health and wellbeing.

EVERY DAY MORE THAN

1 MILLION PEOPLE

contract sexually transmitted
infections (STIs)
CANCER
that can cause:
INFERTILITY

PREGNANCY
COMPLICATIONS
INCREASED
HIV RISK

SOURCES:
Singh, S., J.E. Darroch, and L.S. Ashford. 2014. Adding It Up: The Costs and Benefits of Investing in Sexual and
Reproductive Health 2014. New York: Guttmacher Institute.
UNAIDS. 2014. The Gap Report. Geneva: UNAIDS.
World Health Organization. 2013. “Sexually transmitted infections (STIs).” Fact sheet. Geneva: WHO.
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president’s message

Research and
Development
to Improve
Reproductive
Health

by Julia Bunting
Since it was founded in 1956, the
Population Council’s Center for
Biomedical Research (CBR) has
specialized in researching and
developing drugs, technologies,
and products that enable women,
men, and young people to protect
and enhance their reproductive
health and wellbeing. Hundreds of
millions of women have used a family
planning method developed by the
Council, including the Copper T IUD,
the Mirena® intrauterine system, the
implants Norplant® and Jadelle®,
and the progesterone contraceptive
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vaginal ring for breastfeeding women.
Since the beginning of the HIV
epidemic in the 1980s, the Council
has also conducted research to identify
new, user-controlled methods to
prevent HIV infection.
Today, Council scientists at CBR are
researching new technologies—rings,
gels, and other systems—to provide
even greater contraceptive choice
as well as protection from HIV and
other sexually transmitted infections.
My colleagues identify leads for new
products, develop the most promising
ideas through years of research, work
with regulatory authorities to secure
approval for these technologies, and
collaborate with pharmaceutical
companies, governments, and a
host of other partners to bring these
products to market. This work is
literally improving the lives of millions

of people around the world today and
the benefits of these investments will
continue for generations to come.
In this issue of Momentum you will
read about the Council’s rich and
distinguished history of biomedical
research and the significant impact
of this work on women’s reproductive
health (page 4). You will see how the
Council continues to be at the cutting
edge of developing new contraceptive
vaginal rings (page 10), as well as the
Council’s work to expand access to
long-acting reversible contraception
(page 12). Council researchers are
also exploring innovative contraceptive methods for men (page 6), and
multipurpose prevention technologies
to protect against various sexual and
reproductive health risks (page 8).
You will meet Council scientist José
Fernández Romero, who is identifying

new ways to prevent HIV and other sexually transmitted infections (page 14),
and Barbara Ebert, a decades-long supporter of the Council’s work to develop
new contraceptive methods (page 15).
I am deeply honored to have joined
the Population Council, and I am
committed to building on our strong
legacy and investing in a bright future
of biomedical research.

Together we will continue
to provide women, men,
and young people around the
world with new products to
safeguard their wellbeing and
help them live more productive,
healthier lives.
Thank you for your support.
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tion technologies (MPTs) continues to
evolve. The Council is now advancing
promising options for user-controlled
prevention of HIV and other STIs, as well
as MPTs that provide contraception in
addition to HIV and/or STI prevention.

FROM BENCH TO Bedroom:

BIOMEDICAL
RESEARCH AT THE
POPULATION COUNCIL
The Population Council’s Center for
Biomedical Research (CBR) is at the
vanguard of global research and development (R&D) efforts focusing on contraception, preventing HIV and other sexually
transmitted infections (STIs), and identifying novel approaches to improve health.
The Council helped establish the field
of long-acting, reversible contraception
(LARC) in the early 1960s, working with
international partners to develop the “T”
shape of the modern intrauterine device
(IUD) and identifying the contraceptive action of copper. The Council’s first Copper
T IUD was approved by the US Food and
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Drug Administration in 1976; in 1984,
the FDA approved the Council’s 10-year
Copper T380 IUD (ParaGard®)—the
most popular nonsurgical contraceptive
method used worldwide.
Contraceptive implant technology was
another breakthrough spearheaded
by the Council in the mid-1960s, culminating in the five-year hormonal
implant systems known as Norplant®
and Jadelle® (approved by the FDA in
1990 and 1996, respectively). Other
LARC methods pioneered by Council
researchers and partners include the
five-year Mirena® intrauterine system
and a three-month progesterone vagi-

In 1956 the Population
Council established one
of the first laboratories
dedicated to the research
and development of new
technologies to protect
reproductive health.

nal ring (Progering®) that can be used
by breastfeeding women.
In parallel Council scientists have conducted biomedical research on the
sexual transmission of HIV and worked
toward development of new prevention
technologies ever since HIV infection
and AIDS were recognized as emerging
public health crises in the 1980s. The
Council’s Carraguard® gel was the first
product developed as a microbicide to
complete a Phase III efficacy trial—a
milestone in HIV prevention research.
Although Carraguard was not found to
be effective for HIV prevention, R&D for
microbicides and multipurpose preven-

Today CBR is a vibrant hub of R&D on
the campus of Rockefeller University
in New York City—and the need for new
sexual and reproductive health technologies is just as urgent now as it was
nearly 60 years ago. The R&D process
is long and complex, particularly when
products are being developed for lowresource settings where diverse needs
and challenges must be addressed.
Council discoveries have led to identifying potential added health benefits
of several products in the pipeline,
such as protective effects of novel
contraceptive hormones on breast
and prostate health. Basic science research at CBR has also opened doors
to exploring new treatments for chronic
conditions such as uterine fibroids and
multiple sclerosis.
The Council proudly invests in the
full R&D lifecycle, taking a “bench to
bedroom” approach that focuses on
end-users from the start and works
with partners to identify and fill product
niches that are otherwise not profitable
for traditional biotechnology or pharmaceutical companies. The Council’s R&D
efforts lead to safe and effective products that are acceptable, accessible,
and designed to meet people’s varying
sexual and reproductive health needs
at different points in their lives.
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MALE
CONTRACEPTION
IN DISCOVery
Researchers at the Population
Council are developing a one-year
hormonal contraceptive implant
for men containing the novel
androgen MENT®.

THE PROBLEM

There is a recognized need for long-acting reversible
contraception (LARC) for men, but as yet
there are no available methods. Studies suggest that women and men would
enthusiastically welcome additional male
contraceptive choices, which would enable men to better share the responsibility, risks, and costs of family planning.
The male reproductive system offers
several potential targets for both hormonal and non-hormonal contraception;
however, many challenges exist including
the necessity of stopping daily production of millions of sperm. A safe, effective, acceptable male LARC requires an
approach that will reduce sperm count
without daily use.
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THE PROGRESS

Through the development of MENT from a synthetic steroid
that resembles testosterone, researchers have discovered that administering
an androgen (a male sex hormone) in
combination with a synthetic progestin
(another hormone) can reduce sperm
count without impairing a man’s sex drive.
The Council tested this approach in early
clinical studies, which showed promising
results by inhibiting sperm production
using four MENT implants in healthy
men. The next step will be a randomized
study to evaluate the safety and efficacy
of MENT, either alone or in conjunction with the injectable progestin known
as DMPA (Depo-Provera®), to determine
whether the combination of MENT and a
®

synthetic progestin reduces sperm count
more quickly and effectively.

THE IMPACT New, effective options
for male contraception would expand the
mix of available family planning methods.
Among men who reported being interested in using male contraception, 30%
said they would prefer implants. Unlike
testosterone, MENT does not enlarge the
prostate; and because of its high potency,
a low daily dose can be administered,
making delivery through an implant system preferable for long-term use. Discovery of the second active component will
take the MENT implant technology one
step closer to becoming a viable LARC
option for men.

PartneRS Bayer Schering HealthCare;

Christina Wang (David Geffen School of
Medicine, University of California, Los
Angeles); Crystal Pharma; David T. Baird
(U.K. Medical Research Council [MRC] Centre
for Reproductive Health at the University of
Edinburgh [formerly the MRC Reproductive
Biology Unit]); Eberhard Nieschlag (Center
for Reproductive Medicine and Andrology of
the University Hospital of Munster, Germany);
Horacio Croxatto (Instituto Chileno de
Medicina Reproductiva [ICMER], Santiago,
Chile); Richard Anderson (U.K. MRC Centre
for Reproductive Health at the University of
Edinburgh)

DonorS U.S. National Institutes of Health
Eunice Kennedy Shriver National Institute of
Child Health and Human Development; The
George J. Hecht Fund; The Lita Annenberg
Hazen Foundation; The William and Flora
Hewlett Foundation; Population Council

7

The Population Council is
developing multipurpose
prevention technologies to
protect against HIV and other
sexually transmitted infections,
and in some cases also provide
contraception, with a single
product.

multipurpose
prevention
technologies
IN EARLY-STAGE
DEVELOPMENT
THE PROBLEM

Male and female
condoms are currently the only available products designed to provide concurrent protection against pregnancy
and sexually transmitted infections
(STIs), including HIV. Condoms are effective when used correctly, but there
are many barriers to use and they are
not practical for women and couples
who want to have children. New products are needed to address the needs
of women and men at risk for STIs, HIV,
and unintended pregnancy.

THE PROGRESS

The Population
Council has long-acting vaginal rings
and on-demand multipurpose prevention technologies (MPTs) in varying stages of development. Several candidates
contain a combination of MIV-150 (M),
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an antiretroviral (ARV) drug that prevents
HIV from infecting target cells; zinc acetate
(Z), an antiviral agent with activity against
HIV and genital herpes simplex virus
(HSV-2); and carrageenan (C), a seaweedderived compound active against human
papillomavirus (HPV). The MZC vaginal
ring is designed to prevent HIV and other
STIs for 90 days; the MZCL ring offers
these same potential benefits and adds
the contraceptive levonorgestrel (L) to prevent pregnancy. The Council has produced
and tested prototype rings in preclinical
and animal studies with promising results
and recently completed a Phase I clinical
safety trial of an MZC vaginal gel. A nonARV ZC gel has also been found to be safe
and active against HIV, HPV, and HSV-2 in
preclinical studies. Products are also being developed with griffithsin, a naturally

occurring algae protein shown to be safe
and highly effective against HIV in the lab
and against HSV-2 and HPV in preclinical
studies. A griffithsin gel is being tested to
help develop a sustained-release vaginal
ring and a nanofiber delivery system (a
film-like formulation) to provide protection
at the time of sex. The first human studies
of griffithsin vaginal gel are expected to
begin in 2016.

THE IMPACT

If proven effective, these
MPTs could contribute substantially to
global health. MZC-based products could
increase protection against HIV and HSV-2
at lower doses, which in turn could improve product safety, decrease chances
of drug resistance, and reduce costs.
Non-ARV-based MPT products (e.g., those
containing ZC or griffithsin) could help to

reduce the emergence of drug-resistant
HIV types, eliminate the need for HIV
screening prior to use, and potentially
be provided over-the-counter. Council
researchers are working with academic,
nonprofit, and industry experts to advance promising candidates through the
pipeline and to identify strategies for
introduction and scale-up to ensure that
MPTs, once available, are accessible to
those most in need.
COLLABORATORS Duke University;
Fraunhofer Center for Molecular Biotechnology;
ProMed Pharma; Tulane National Primate
Research Center; University of Alabama at
Birmingham; University of Washington
Donors U.S. National Institutes of Health

National Institute of Allergy and Infectious
Diseases; U.S. President’s Emergency Plan for
AIDS Relief (PEPFAR); United States Agency for
International Development (USAID); Sweden
Ministry for Foreign Affairs
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contraceptive
vaginal rings
IN Late-STAGE
DEVELOPMENT
The Population Council has developed two
innovative contraceptive vaginal rings to
meet women’s varying family planning needs:
a three-month ring that contains progesterone
for use by breastfeeding women, and an
investigational one-year ring that can prevent
pregnancy for a full year.
THE PROBLEM

Women in lowresource settings face unique barriers to
obtaining effective contraception, including limited access to different options
and a lack of trained health professionals
to provide services or counseling. In addition, although exclusive breastfeeding
may prevent pregnancy for the first six
months after childbirth, return to fertility
can occur sooner than anticipated, leaving women at risk for unintended pregnancy, unsafe abortion, and poor health
outcomes. There is an urgent need for
convenient new contraceptive methods
that are safe, effective, easy to use, and
under a woman’s control.

THE PROGRESS The Council’s
three-month progesterone vaginal ring
(PVR) can be used safely by breastfeed10

ing women to help space pregnancies.
It does not affect lactation and does not
require insertion by a healthcare provider.
Each PVR can be used continuously for
three months, and rings can be used successively for up to a year. Fertility returns
shortly after removal. The ring has been
available in Latin America since 1998
under the brand name Progering®. The
Council is working to introduce the PVR
in more countries where prolonged lactation is vital for infant health—and where
access to highly effective contraceptives
is limited.
The one-year ring prevents pregnancy by
releasing a low dose of ethinyl estradiol
(EE), an approved, marketed hormonal
product, and Nestorone® (NES), an investigational progestin that has been shown

to be highly effective in preventing ovulation. The NES/EE ring is inserted by the
woman, left in place for 21 days, and removed for 7 days. One ring can be used for
up to 13 cycles (one year), and fertility returns after discontinuing use. The Council
is preparing to submit a New Drug Application to the US Food and Drug Administration and will seek to introduce the one-year
NES/EE ring in various settings, including
in low- and middle-income countries.

THE IMPACT

The PVR is currently
available to women in Bolivia, Chile, Colombia, Dominican Republic, Ecuador,
Guatemala, Honduras, and Peru, and the
market is now expanding to include regulatory applications in Brazil and Mexico. The
Council is also working toward product
introduction in India, Kenya, Nigeria, and

Senegal, with the goal of expanding to
other countries. The Council’s one-year
NES/EE ring, if approved by the FDA,
would be a unique long-acting reversible
contraceptive that is effective for 13
cycles, is under the woman’s control,
and does not require insertion or removal by a trained healthcare provider.
Partners Bill & Melinda Gates Institute
for Population and Reproductive Health;
Grünenthal (formerly Andromaco); International
Committee for Contraception Research;
Ministries of Health of India, Kenya, Nigeria,
and Senegal; QPharma; WomenCare Global;
World Health Organization
Donors Barrus Foundation; Bill & Melinda
Gates Foundation; U.S. Agency for International
Development; U.S. National Institutes of Health
Eunice Kennedy Shriver National Institute
of Child Health and Human Development
Contraceptive Clinical Trials Network
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DELIVERING ON A PROMISE:

THE ICA FOUNDATION
THE PROBLEM

The levonorgesterel
intrauterine system (LNG IUS) provides
up to five years of safe, effective, and
continuous contraception. Developed
by the Population Council and Finlandbased Bayer OY, the LNG IUS is distributed by Bayer HealthCare Pharmaceuticals in the private market under the
trade name Mirena® in more than
120 countries. In low-resource settings,
the LNG IUS is often inaccessible due
to financial barriers and supply chain
challenges.

no cost in resource-poor settings.
To date, the Foundation has provided
over 67,000 LNG IUS and training materials to projects in 28 low- and middleincome countries. To become a project
of the Foundation, eligible organizations
must submit an application describing
their plans for integrating the LNG IUS
into their reproductive health service
delivery activities. This local responsibility ensures that the donated LNG IUS
are distributed in a culturally-appropriate and acceptable manner.

THE PROGRESS

THE IMPACT

The ICA
Foundation was established in 2003
to help overcome these obstacles
by making the LNG IUS available at
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Two of the ICA Foundation’s most successful projects are
highlighted here to illustrate the impact
of this important work.

The International Contraceptive
Access (ICA) Foundation, a public–
private partnership between the
Population Council and Bayer OY, is
helping expand access to long-acting
reversible contraception in lowresource settings.

BRAZIL: Since becoming an ICA Foundation project in 2006, the Center for
Research in Reproductive Health of
Campinas (CEMICAMP) and the University of Campinas School of Medicine’s
Department of Obstetrics and Gynecology (UNICAMP) has provided an average
of 271 women per month with free LNG
IUS insertions at more than 20 sites
throughout Brazil. It is the Foundation’s
largest project, having received nearly
21% of all LNG IUS donations made in
the past decade (over 14,000 devices)
and trained nearly 100 health professionals across Brazil on counseling and
insertion/removal techniques. The project is led by Prof. Dr. Luis Bahamondes,
an eminent OB/GYN based in Campinas.

NIGERIA: With 35 sites across Nigeria,
Rotary International has received 7,500
LNG IUS donations since becoming an ICA
Foundation project in 2007. Local partners
have developed and implemented health
provider education and community
outreach activities involving men and religious leaders in family planning promotion, and women served by project sites
report very high acceptance of the LNG
IUS. The project is led by Robert Zinser,
Chief Executive Officer of the Rotarian
Action Group for Population and Development and a long-standing champion for
maternal health and family planning.
Donors Bayer HealthCare Pharmaceuticals,
Population Council
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A CONVERSATION WITH

JOSÉ FernÁndez Romero

BARBARA EBERT

SCIENTIST AT THE POPULATION COUNCIL’S
CENTER FOR BIOMEDICAL RESEARCH (CBR)

Council Donor

Tell us about the work you do.
I lead the preclinical virology group in
the microbicides laboratory at CBR. We
conduct research to identify compounds
that might be active against HIV and other
sexually transmitted pathogens such as
genital herpes simplex virus (HSV-2) and
human papillomavirus (HPV). After one or
more compounds has been formulated
as a product candidate (for example, as
you read about on page 8) and before
any human testing is done, we conduct
rigorous studies on these microbicide and
multipurpose prevention technology (MPT)
candidates to ensure they are safe and
effective. These preclinical studies are necessary in order to identify the most promising microbicide and MPT candidates to be
further developed and tested in people.

Why did you choose to do this work
at the Council?
The Population Council has a rich history
of improving the lives and expectations
of millions of people. Our HIV prevention
program follows the same philosophy of
empowering the world’s most vulnerable
by working to make user-controlled
microbicides and MPTs a reality.

What led you to enter the field of
biomedical research?
My passion for virology started 20 years
ago when I began studying microbiology.
This was back in the 1990s, when people
14
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began paying more attention to the global
impact of HIV and AIDS. After I received
my bachelors degree in microbiology
at the University of Havana, I stayed to
teach virology and genetic engineering
while conducting research on indigenous
plants and their potential for antiviral activity. Soon after I arrived in the US from
Cuba, the Council introduced me to the
new idea of HIV prevention through microbicides, and I decided to use my expertise in virology to serve the microbicide
research community. Today my goal is to
help develop potential MPTs that protect
women and men not only from HIV but
also other sexually transmitted infections
(STIs) and unintended pregnancy.

What has been most rewarding
for you in your career?
I have enjoyed helping build a team with
the unique expertise to test potential
products against three major, noncurable viral STIs. I am lucky to work with
colleagues who understand the importance of teamwork and are passionate
about the work we do. I also teach biology and microbiology at Hostos Community College in the Bronx—a gratifying experience for me, especially when some of
my students, many of whom are minorities, decide to pursue a career in biology.
I hope that by teaching at Hostos, I can
make a modest contribution to raise the
profile of minorities in the sciences.

I give to the Population Council
because of the long association my late
husband, Dr. Robert Ebert, had with
the organization—30 years as a board
member, 10 years as chair. He considered
the Population Council one of the most
important and effective organizations he
had the privilege of serving.
Bob spent his career in academic
medicine―as bench scientist, clinician,
and medical school dean. He worked
on new drugs to treat tuberculosis and
was continually challenged to translate
his research to the bedside as quickly
as possible. He saw how new drugs
improved people’s lives. He cared deeply
about public health issues, including
efficient and cost-effective delivery of
medical care to needy populations,
prevention of communicable diseases,
and family planning. Becoming a trustee
of the Population Council extended his
interest in public health to the global
level. He became even more committed to
developing new products and initiatives to
improve the reproductive health of women
in developing nations.
It was my privilege and good fortune to
accompany him on some board meetings
in Africa. One took us to Senegal and
Mali, where we visited clinics for and
managed by women. These women
stressed the importance of good health,
prenatal care, and family planning. When

WHY I GIVE TO THE
POPULATION COUNCIL
we arrived at one clinic, the clients,
having been told that Population
Council Trustees were coming to visit,
were waiting for us all dressed up. They
passed their babies to us to hold and
coo over (in fractured French for most
of us). They used theater to illustrate
the important health issues they faced;
we saw two skits in which women
impressed upon their husbands the
importance of family planning. They
played these parts with a good deal
of humor—including an irate mother
who browbeat her son for getting his
wife pregnant again—and were very
effective in putting their point across.
While I make modest gifts to other
family planning organizations, I am
particularly impressed with the broad
scope of the Council’s influence
throughout the world. Family planning
is obviously one, but the work of the
Center for Biomedical Research in
developing safe, innovative, and affordable contraceptives has made a huge
impact in this area. Addressing other
issues such as HIV prevention, education and safe spaces for girls, and poverty alleviation makes the Population
Council stand out as a leader.
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WITH YOUR HELP, WE CAN
CONTINUE TO PROVIDE
PEOPLE WITH NEW PRODUCTS
TO SAFEGUARD THEIR
REPRODUCTIVE HEALTH AND
WELLBEING.
Support the
Population Council:

popcouncil.org/supporting
Sign up for the Council’s
e-mail list:

popcouncil.org

(Click “Subscribe” on the homepage)
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